SEC 13F Intelligence

Managers / Q3 2022 · view latest →

Rhenman & Partners Asset Management AB

CIK 0001599882 · STRANDVAGEN 5A, STOCKHOLM, 11451 · 4684598880

Reported Value
$955M
Q3 2022
Positions
90
Filings on Record
31
2019–present window
Filed
Nov 14, 2022
original filing

Summary

Rhenman & Partners Asset Management AB reported $955M in U.S.-listed holdings across 90 positions for Q3 2022.

Its largest position, LLY, represents 3.7% of the portfolio.

Compared with Q2 2022, the fund opened 8 new positions and exited 4.

Portfolio Metrics

Turnover
+12.1%
vs prior filed quarter
Top-10 Concentration
+28.2%
share of reported value
Largest Position
+3.7%
Lilly Eli
New / Exited
8 / 4
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $875MQ4 ’18Q1 ’19: $855MQ2 ’19: $908MQ3 ’19: $798MQ4 ’19: $913MQ4 ’19Q1 ’20: $714MQ2 ’20: $926MQ3 ’20: $1.1BQ4 ’20: $1.2BQ4 ’20Q1 ’21: $1.4BQ2 ’21: $1.5BQ3 ’21: $1.4BQ4 ’21: $1.5BQ4 ’21Q1 ’22: $1.0BQ2 ’22: $880MQ3 ’22: $955MQ4 ’22: $958MQ4 ’22Q1 ’23: $911MQ2 ’23: $949MQ3 ’23: $928MQ4 ’23: $1.0BQ4 ’23Q1 ’24: $1.1BQ2 ’24: $1.0BQ3 ’24: $1.2BQ4 ’24: $973MQ4 ’24Q1 ’25: $870MQ2 ’25: $791MQ3 ’25: $904MQ4 ’25: $1.1BQ4 ’25Q1 ’26: $810Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 88.0%Other: 9.7%ADR: 2.3%
  • Common Stock · 88.0% · $840M
  • Other · 9.7% · $93M
  • ADR · 2.3% · $22M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
BIIBBIOGEN INCNEW+32.8K32.8K+$9M$9M
PODDINSULET CORPNEW+29.0K29.0K+$8M$8M
NVSTENVISTA HOLDINGS CORPORATIONNEW+143.8K143.8K+$5M$5M
KARUNA THERAPEUTICS INCNEW+20.0K20.0K+$4M$4M
WSTWEST PHARMACEUTICAL SVSC INCNEW+17.0K17.0K+$4M$4M
NTRANATERA INCNEW+80.0K80.0K+$4M$4M
ALHCALIGNMENT HEALTHCARE INCNEW+274.9K274.9K+$4M$4M
TXG10X GENOMICS INCNEW+75.0K75.0K+$2M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2022

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1LLYLILLY ELI & COhistory →COM3.68%$35M97.0K
2UNHUNITED HEALTH GROUP INChistory →COM3.19%$30M54.8K
3BSXBOSTON SCIENTIFIC CORPhistory →COM3.14%$30M695.0K
4VRTXVERTEX PHARMACEUTICALS INChistory →COM3.14%$30M96.0K
5TMOTHERMO FISHER SCIENTIFIC INChistory →COM2.83%$27M52.5K
6HUMHUMANA INChistory →COM2.57%$25M44.0K
7CICIGNA CORP NEWhistory →COM2.54%$24M75.0K
8REGNREGENERON PHARMACEUTICALShistory →COM2.51%$24M32.0K
9ABBVABBVIE INChistory →COM2.29%$22M149.6K
10ELVELEVANCE HEALTH INChistory →COM2.29%$22M40.0K
11MRKMERCK & CO. INChistory →COM2.28%$22M215.0K
12ABMDEURABIOMED INChistory →COM2.27%$22M85.9K
13ABGAMERISOURCEBERGEN CORPhistory →COM2.24%$21M136.0K
14CVSCVS HEALTH CORPhistory →COM2.23%$21M225.0K
15GILDGILEAD SCIENCES INChistory →COM2.22%$21M270.0K
16MEDTRONIC PLCSHS2.19%$21M240.0K
17BMRNBIOMARIN PHARMACEUTICAL INChistory →COM2.15%$21M237.0K
18BDXBECTON DICKINSON & COhistory →COM2.10%$20M85.0K
19MCKMCKESSON CORPhistory →COM2.04%$19M50.0K
20JAZZ PHARMACEUTICALS PLCSHS USD1.98%$19M131.5K
21JNJJOHNSON & JOHNSONhistory →COM1.82%$17M100.0K
22PFEPFIZER INChistory →COM1.71%$16M350.0K
23DHRDANAHER CORPORATIONhistory →COM1.63%$16M62.0K
24ALNYALNYLAM PHARMACEUTICALS INChistory →COM1.63%$16M75.0K
25AXNX*AXONICS INChistory →COM1.61%$15M210.0K
26THCTENET HEALTHCARE CORPhistory →COM NEW1.60%$15M344.0K
27BNTXBIONTECH SEhistory →SPONSORED ADS1.43%$14M99.0K
28APLSUSDAPELLIS PHARMACEUTICALS INChistory →COM1.39%$13M220.0K
29MRTXEURMIRATI THERAPEUTICS INChistory →COM1.39%$13M197.1K
30COOPER COS INCCOM NEW1.34%$13M46.9K
31ISRGINTUITIVE SURGICAL INChistory →COM NEW1.29%$12M50.0K
32HRMYHARMONY BIOSCIENCES HLDGS INhistory →COM1.29%$12M237.0K
33INSPINSPIRE MED SYS INChistory →COM1.29%$12M63.0K
34ABTABBOTT LABShistory →COM1.21%$12M117.0K
35NBIXNEUROCRINE BIOSCIENCES INChistory →COM1.00%$10M83.0K
36HCAHCA HEALTHCARE INCCOM0.98%$9M43.0K
37BIIBBIOGEN INCCOM0.97%$9M32.8K
38PRVAPRIVIA HEALTH GROUP INCCOM0.97%$9M277.0K
39CYTKCYTOKINETICS INCCOM NEW0.96%$9M210.0K
40ROYALTY PHARMA PLCSHS CLASS A0.95%$9M215.0K
41EWEDWARDS LIFESCIENCES CORPCOM0.95%$9M125.0K
42OPHTEURIVERIC BIO INCCOM0.91%$9M365.0K
43RVNCEURREVANCE THERAPEUTICS INCCOM0.91%$9M388.0K
44IMCRIMMUNOCORE HLDGS PLCADS0.90%$9M150.0K
45DVAXDYNAVAX TECHNOLOGIES CORPCOM NEW0.88%$8M733.5K
46XNCRXENCOR INCCOM0.86%$8M294.1K
47HORIZON THERAPEUTICS PUB LSHS0.85%$8M130.0K
48PODDINSULET CORPCOM0.79%$8M29.0K
49ESPRESPERION THERAPEUTICS INC NECOM0.77%$7M900.0K
50SILKUSDSILK RD MED INCCOM0.72%$7M155.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$810M86May 14, 202613F-HRchanges · EDGAR ↗
Q4 2025$1.1B94Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$904M92Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$791M90Aug 13, 202513F-HRchanges · EDGAR ↗
Q1 2025$870M94May 14, 202513F-HRchanges · EDGAR ↗
Q4 2024$973M92Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$1.2B95Nov 13, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.0B93Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$1.1B84May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$1.0B85Feb 13, 202413F-HRchanges · EDGAR ↗
Q3 2023$928M85Nov 13, 2023RESTATEMENTchanges · EDGAR ↗
Q2 2023$949M83Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$911M88May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$958M93Feb 13, 202313F-HRchanges · EDGAR ↗
Q3 2022$955M90Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$880M86Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.0B89May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.5B92Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.4B92Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.5B94Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.4B92May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.2B83Jan 19, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.1B82Oct 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$926M94Jul 16, 202013F-HRchanges · EDGAR ↗
Q1 2020$714M85Apr 16, 202013F-HRchanges · EDGAR ↗
Q4 2019$913M94Jan 17, 202013F-HRchanges · EDGAR ↗
Q3 2019$798M93Oct 16, 201913F-HRchanges · EDGAR ↗
Q2 2019$908M88Jul 22, 201913F-HRchanges · EDGAR ↗
Q1 2019$855M93Apr 11, 201913F-HRchanges · EDGAR ↗
Q4 2018$875M89Feb 5, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.